Johnson & Johnson’s COVID-19 vaccine has hit a production hurdle – potentially delaying the delivery of millions of wildfires by two months, according to a report on Wednesday.
The pharmaceutical giant, which has promised to make 12 million single-dose shots available by the end of February, has warned health officials that the company is lagging behind, according to Politico.
It is likely that Johnson & Johnson will take until the end of April to reach that original projection, said an informed person on the matter.
But a representative of the pharmaceutical giant denied that it is facing a slowdown in production – saying that the company is “confident in our ability to meet our supply commitments for 2021”.
“We remain in active discussions with regulators, including on the approval and validation of our manufacturing processes,” the representative said. “Operation Warp Speed is working with Johnson & Johnson to expand and maximize the production of the Janssen vaccine … Projections are premature at this time.”
On Monday, Warp Speed co-director Moncef Slaoui suggested there could be a delay in Johnson & Johnson’s initial $ 12 million target, saying “single-digit” doses will likely be delivered in the second half of the month. February.
The company, which has pledged to release 100 million doses by the end of June, will seek FDA emergency approval for its COVID-19 vaccine candidate later this month.
The Johnson & Johnson vaccine is seen as critical to partially fighting the pandemic because it requires a single dose – and should not be kept at sub-zero temperatures.
Instead, Pfizer and Moderna vaccines require two separate doses. The Pfizer vaccine should be kept at minus 94 degrees Fahrenheit.